A detailed history of Platinum Investment Management LTD transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Platinum Investment Management LTD holds 157,851 shares of COGT stock, worth $1.7 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
157,851
Previous 186,254 15.25%
Holding current value
$1.7 Million
Previous $1.25 Million 6.31%
% of portfolio
0.05%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$6.01 - $9.04 $170,702 - $256,763
-28,403 Reduced 15.25%
157,851 $1.33 Million
Q1 2024

May 13, 2024

SELL
$4.38 - $9.02 $1.27 Million - $2.61 Million
-289,380 Reduced 60.84%
186,254 $1.25 Million
Q4 2023

Feb 13, 2024

SELL
$4.06 - $10.08 $824 - $2,046
-203 Reduced 0.04%
475,634 $2.8 Million
Q3 2023

Nov 02, 2023

SELL
$9.69 - $13.34 $12,044 - $16,581
-1,243 Reduced 0.26%
475,837 $4.64 Million
Q1 2023

May 11, 2023

SELL
$10.04 - $15.5 $344,472 - $531,805
-34,310 Reduced 6.71%
477,080 $5.15 Million
Q3 2022

Nov 14, 2022

SELL
$9.39 - $16.99 $3.66 Million - $6.63 Million
-390,022 Reduced 43.27%
511,390 $7.63 Million
Q2 2022

Aug 11, 2022

SELL
$3.92 - $9.73 $585,205 - $1.45 Million
-149,287 Reduced 14.21%
901,412 $8.13 Million
Q4 2021

Feb 11, 2022

BUY
$7.51 - $10.81 $513,691 - $739,414
68,401 Added 6.96%
1,050,699 $9.02 Million
Q3 2021

Nov 09, 2021

BUY
$5.99 - $9.14 $935,512 - $1.43 Million
156,179 Added 18.91%
982,298 $8.26 Million
Q2 2021

Aug 11, 2021

BUY
$7.82 - $9.3 $736,769 - $876,208
94,216 Added 12.87%
826,119 $6.7 Million
Q1 2021

May 13, 2021

BUY
$7.47 - $12.34 $1.91 Million - $3.16 Million
256,198 Added 53.86%
731,903 $6.43 Million
Q4 2020

Feb 12, 2021

BUY
$9.04 - $13.01 $4.3 Million - $6.19 Million
475,705 New
475,705 $5.34 Million

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $710M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Platinum Investment Management LTD Portfolio

Follow Platinum Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Platinum Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Platinum Investment Management LTD with notifications on news.